PUBLISHER: The Business Research Company | PRODUCT CODE: 1662969
PUBLISHER: The Business Research Company | PRODUCT CODE: 1662969
Critical limb ischemia treatment involves the restoration of blood flow to areas affected by critical limb ischemia, a chronic condition characterized by severe blockages in the blood vessels of the hands and legs, leading to numbness and pain. Treatment modalities encompass a range of approaches, including medication, surgical interventions using devices, and other therapeutic measures.
The primary types of critical limb ischemia treatment include devices, drugs, and surgery. Embolic protection devices (EPDs) are medical devices designed to trap blood and luminal debris, preventing plaque debris from reaching the distal bed. Medications used in the treatment include antihypertensive agents, antiplatelet drugs, antithrombotic agents, and others. These treatments are administered in various healthcare settings, including hospitals, clinics, and other medical facilities.
The critical limb ischemia market research report is one of a series of new reports from The Business Research Company that provides critical limb ischemia market statistics, including critical limb ischemia industry global market size, regional shares, competitors with a critical limb ischemia market share, detailed critical limb ischemia market segments, market trends and opportunities, and any further data you may need to thrive in the critical limb ischemia industry. This critical limb ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The critical limb ischemia market size has grown strongly in recent years. It will grow from $3.6 billion in 2024 to $3.9 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increase in diabetes cases, tobacco consumption, hypertension prevalence, improvements in vascular imaging, growth in endovascular interventions, medical research and clinical trials.
The critical limb ischemia market size is expected to see strong growth in the next few years. It will grow to $5.57 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to regenerative medicine advances, focus on early intervention, increasing prevalence of obesity, global health initiatives, patient education program. Major trends in the forecast period include wearable health technologies, telemedicine and remote patient monitoring, integration of artificial intelligence (AI), patient-centric care models, minimally invasive interventions.
The anticipated surge in diabetes mellitus and peripheral artery diseases is poised to drive the expansion of the critical limb ischemia treatment market in the foreseeable future. Diabetes mellitus characterizes a metabolic disorder involving elevated blood glucose levels, while peripheral artery disease refers to the narrowing of leg arteries, leading to reduced blood flow to the limbs. These conditions significantly heighten the risk of vascular complications and amputation, thereby contributing to the occurrence of critical limb ischemia. The escalating prevalence of diabetes mellitus and peripheral artery diseases acts as a driving force behind the growth of the critical limb ischemia market. For example, as per data from the International Diabetes Federation in January 2022, the global prevalence of diabetes among 20-79-year-olds reached 536.6 million in 2021, expected to rise by 12.2% to 783.2 million by 2045. Furthermore, a journal published by Oxford University Press in March 2023 indicated that over 200 million individuals were affected by peripheral artery diseases in 2020, projected to surge by nearly 50% by 2045. Hence, the increasing incidence of these diseases fuels the critical limb ischemia treatment market.
Leading companies in the critical limb ischemia (CLI) treatment market are innovating advanced products, such as dissolving stents, to improve treatment outcomes for patients affected by this severe type of peripheral artery disease. Dissolving stents, known as bioresorbable stents, are designed to offer temporary support to the affected artery and gradually dissolve as the vessel heals. For instance, in April 2024, Abbott Laboratories, a US-based medical device company, received approval from the Food and Drug Administration (FDA) for the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This stent is specifically aimed at patients with chronic limb-threatening ischemia (CLTI) in arteries below the knee. This approval signifies the first time a dissolving stent has been authorized for this condition in the United States. Made from materials similar to dissolving sutures, the stent is engineered to dissolve over approximately three years after implantation. It also releases the immunosuppressive drug everolimus, which helps prevent the re-narrowing of arteries and supports the healing of the vessel.
Major companies in the critical limb ischemia (CLI) treatment market are developing technologically advanced products, such as dissolving stents, to enhance treatment outcomes for patients with this severe form of peripheral artery disease. Dissolving stents, also referred to as bioresorbable stents, are engineered to provide temporary support to the affected artery and gradually dissolve as the vessel heals. For example, in April 2024, Abbott Laboratories, a US-based medical device manufacturer, received approval from the Food and Drug Administration (FDA) for the Esprit BTK Everolimus Eluting Resorbable Scaffold System. This dissolving stent is intended for patients suffering from chronic limb-threatening ischemia (CLTI) in arteries below the knee. This approval marks the first instance of a dissolving stent being approved for this condition in the United States. The stent is constructed from materials similar to those used in dissolving sutures and is designed to dissolve over approximately three years following implantation. It also releases the immunosuppressive drug everolimus, which aids in preventing the re-narrowing of arteries and promotes vessel healing.
Key players in the critical limb ischemia market are strategically focusing on innovative solutions, such as a clinically engineered immobilization solution for the patient's leg, to establish a competitive edge in the market. These solutions delicately immobilize the patient's leg during fluoroscopy-guided treatments, providing crucial pressure management for individuals prone to painful ulcerations. For instance, in January 2022, Adept Medical, a New Zealand-based medical equipment manufacturer, introduced its Lower Leg Support product. This device is tailored to gently immobilize a patient's leg during fluoroscopy-guided critical limb ischemia treatments. Equipped to perform both endorotation and exorotation, the Lower Leg Support offers versatile positioning options while maintaining the foot in a slightly plantar-flexed posture for optimal imaging. Its ergonomic design aligns the leg to meet procedural requirements for lower limb interventions. The gadget features an adaptable footplate, enabling usage on either the left or right foot. Moreover, if foot manipulation is necessary during the procedure, the footplate can be entirely removed, allowing access for distal artery procedures, ultrasound imaging, and effective pressure management for patients experiencing frequent painful ulcerations. Additionally, the device includes soft foam straps to gently immobilize patients during conscious sedation.
In November 2023, Inari Medical, a US-based medical device company, acquired LimFlow SA for an undisclosed amount. This acquisition is intended to expand Inari Medical's portfolio with innovative technologies that address unmet needs in the treatment of chronic limb-threatening ischemia (CLTI), ultimately enhancing patient outcomes and driving growth. LimFlow SA is a Switzerland-based company specializing in medical devices for the treatment of chronic limb-threatening ischemia (CLTI).
Major companies operating in the critical limb ischemia market include Medtronic Plc, Boston Scientific Corporation, ThermoGenesis Holdings Inc., Abbott Laboratories, Pluri Biotech Ltd., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc., Cynata Therapeutics Ltd, Shanghai MicroPort Medical (Group) Co Ltd., B. Braun SE, Teva Pharmaceutical Industries Ltd., Aldagen Inc., Cook Medical, Philips, BD, Penumbra Inc., Cardinal Health Inc., Teleflex Incorporated, AngioDynamics Inc., Endologix Inc., Terumo Corporation, Teleflex, MicroPort Scientific, Silk Road Medical, LeMaitre Vascular Inc., Merit Medical Systems Inc., Shockwave Medical, Avinger, Biomerics LLC, Intact Vascular Inc., Soundbite Medical Solutions, Bluegrass Vascular Technologies, PQ Bypass, Vasorum Ltd, Rex Medical, Otsuka Medical Devices, Aortica Corporation
North America was the largest region in the critical limb ischemia treatment market in 2024. The regions covered in the critical limb ischemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the critical limb ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The critical limb ischemia treatment market includes revenues earned by entities by providing angioplasty, stents and laser atherectomy treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Critical Limb Ischemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on critical limb ischemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for critical limb ischemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The critical limb ischemia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.